March 11, 2025
Harvard Scientist Dr. David Sinclair Announces Human Trials to Reverse Aging Starting in January 2026

Dr. David Sinclair, a prominent geneticist at Harvard Medical School, has shared major breakthroughs in reversing aging using epigenetic reprogramming. His team has successfully rejuvenated mice and monkeys—particularly restoring optic nerve function—and plans to begin human clinical trials in January 2026, starting with eye conditions such as glaucoma and ischemic optic neuropathy.

The research is based on Sinclair’s Information Theory of Aging, which suggests that aging results not merely from cellular wear but from a loss of epigenetic information—the regulatory instructions for cells. By activating a set of genes known as Yamanaka factors, his team has been able to reset cells to a younger state without erasing their identity.

To scale these therapies, Sinclair’s lab is using artificial intelligence to screen for rejuvenating compounds that could be administered orally, potentially enabling age-reversal treatments via a simple pill.

The implications extend well beyond healthcare. Adding just one extra year of healthy life expectancy could yield trillions in economic benefits, reduce healthcare burdens, and elevate productivity. Yet Sinclair warns of significant obstacles, such as funding limitations, regulatory challenges, and the potential inequity in access to these therapies.

Nevertheless, he remains hopeful, stating: “The first person to live to 150 has already been born.” He emphasizes the need for continued investment—both public and private—to ensure these breakthroughs benefit everyone, not just a privileged few.